Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, April 27, 2023
[ Thu, Apr 27th 2023
] - WOPRAI
[ Thu, Apr 27th 2023
] - WOPRAI
[ Thu, Apr 27th 2023
] - WOPRAI
[ Thu, Apr 27th 2023
] - WOPRAI
[ Thu, Apr 27th 2023
] - WOPRAI
[ Thu, Apr 27th 2023
] - WOPRAI
[ Thu, Apr 27th 2023
] - WOPRAI
[ Thu, Apr 27th 2023
] - WOPRAI
[ Thu, Apr 27th 2023
] - WOPRAI
[ Thu, Apr 27th 2023
] - WOPRAI
[ Thu, Apr 27th 2023
] - WOPRAI
[ Thu, Apr 27th 2023
] - WOPRAI
[ Thu, Apr 27th 2023
] - WOPRAI
[ Thu, Apr 27th 2023
] - WOPRAI
[ Thu, Apr 27th 2023
] - WOPRAI
[ Thu, Apr 27th 2023
] - WOPRAI
[ Thu, Apr 27th 2023
] - WOPRAI
[ Thu, Apr 27th 2023
] - WOPRAI
[ Thu, Apr 27th 2023
] - WOPRAI
[ Thu, Apr 27th 2023
] - WOPRAI
[ Thu, Apr 27th 2023
] - WOPRAI
[ Thu, Apr 27th 2023
] - WOPRAI
[ Thu, Apr 27th 2023
] - WOPRAI
[ Thu, Apr 27th 2023
] - WOPRAI
[ Thu, Apr 27th 2023
] - WOPRAI
[ Thu, Apr 27th 2023
] - WOPRAI
[ Thu, Apr 27th 2023
] - WOPRAI
[ Thu, Apr 27th 2023
] - WOPRAI
[ Thu, Apr 27th 2023
] - WOPRAI
Andreas Argyrides Maintained (BMRN) at Hold with Decreased Target to $69 on, Apr 27th, 2023
Andreas Argyrides of Wedbush, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Hold with Decreased Target from $74 to $69 on, Apr 27th, 2023.
Andreas has made no other calls on BMRN in the last 4 months.
There are 7 other peers that have a rating on BMRN. Out of the 7 peers that are also analyzing BMRN, 3 agree with Andreas's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Kostas Biliouris of "BMO Capital" Maintained at Hold with Decreased Target to $102 on, Tuesday, March 7th, 2023
- Whitney Ijem of "Canaccord Genuity" Maintained at Hold with Decreased Target to $112 on, Tuesday, February 28th, 2023
- Leland Gershell of "Oppenheimer" Downgraded from Buy to Hold on, Wednesday, February 22nd, 2023
These are the ratings of the 4 analyists that currently disagree with Andreas
- William Pickering of "Bernstein" Initiated at Sell and Held Target at $81 on, Tuesday, March 21st, 2023
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $131 on, Tuesday, February 28th, 2023
- Paul Matteis of "Stifel" Maintained at Strong Buy with Increased Target to $118 on, Tuesday, February 28th, 2023
- Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $130 on, Friday, February 3rd, 2023
